Breadcrumb

[A18-36] Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-06-05 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Executive summary of dossier assessment  [PDF, 115 kB] (German version) Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant pages of the G-BA website: Nutzenbewertungsverfahren zum Wirkstoff Olaparib (neues Anwendungsgebiet: high-grade epitheliales Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom) and Nutzenbewertungsverfahren zum Wirkstoff Olaparib (Aufhebung des Orphan-Drug-Status).

Contact address:to the contact form

Report documents

Report documents

PublishedDocumentSizeType 
2018-09-17 Executive summary of dossier assessment (German version) 115 kBPDFdownload file
2018-09-17 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant pages of the G-BA website: Nutzenbewertungsverfahren zum Wirkstoff Olaparib (neues Anwendungsgebiet: high-grade epitheliales Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom) and Nutzenbewertungsverfahren zum Wirkstoff Olaparib (Aufhebung des Orphan-Drug-Status).



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close